Eli Lilly's Wegovy Competitor Is Causing Supply Constraints: What It Means for the Stock
https://www.fool.com/investing/2024/04/06/eli-lillys-wegovy-competitor-is-causing-supply-con/?source=iedfolrf0000001
Apr 06, 2024 - Things are going exactly as planned for the biotech giant.
0
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
https://www.fool.com/investing/2024/04/17/why-eli-lilly-stock-beat-the-market-today-while-re/?source=iedfolrf0000001
Apr 17, 2024 - The company published some very good news from the lab, although it wasn't so encouraging for smaller rivals.
0
Eli Lilly (LLY) Q1 2024 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/04/30/eli-lilly-lly-q1-2024-earnings-call-transcript/?source=iedfolrf0000001
Apr 30, 2024 - LLY earnings call for the period ending March 31, 2024.
0
Move Over, Mounjaro. Eli Lilly Has Another Blockbuster in the Making
https://www.fool.com/investing/2024/05/04/move-over-mounjaro-eli-lilly-has-another-blockbust/?source=iedfolrf0000001
May 04, 2024 - Eli Lilly has made inroads in the red-hot weight-loss market thanks to its diabetes blockbuster, Mounjaro.
0
Eli Lilly takes early lead in weight loss drug race, BMO says
https://seekingalpha.com/news/4051344-eli-lilly-takes-lead-weight-loss-drug-race-bmo?source=feed_sector_healthcare
Dec 29, 2023 - Eli Lilly's (LLY) weight loss drug Zepbound is gaining market traction, challenging competitor Novo Nordisk (NVO). Read more here.
0
Eli Lilly Stock Jumped 59% in 2023. Is It a Good Stock to Buy in 2024?
https://www.fool.com/investing/2023/12/31/eli-lilly-stock-jumped-59-in-2023-is-it-a-good-sto/?source=iedfolrf0000001
Dec 31, 2023 - Sales of its new weight-management drug could be off the charts next year.
0
Missed Out on Eli Lilly? My Best Pharmaceutical Stock to Buy And Hold
https://www.fool.com/investing/2024/01/03/missed-out-eli-lilly-best-pharmaceutical-stock/?source=iedfolrf0000001
Jan 03, 2024 - The past three years were bliss for Eli Lilly shareholders, but those not already on board should look at its rival instead.
0
Eli Lilly’s Jaypirca to lead BTK inhibitor market for leukemia
https://seekingalpha.com/news/4056131-eli-lilly-jaypirca-lead-btk-inhibitor-market-leukemia?source=feed_sector_healthcare
Jan 18, 2024 - Eli Lilly's (LLY) cancer drug, Jaypirca, is expected to dominate the market for BTK inhibitors for chronic lymphocytic leukemia in seven major markets. Read more here.
0
Eli Lilly gene therapy restores hearing in Phase 1/2 trial
https://seekingalpha.com/news/4058092-eli-lilly-gene-therapy-restores-hearing-phase-12-trial?source=feed_sector_healthcare
Jan 24, 2024 - Eli Lilly's (LLY) gene therapy candidate, AK-OTOF, successfully restored hearing in an 11-year-old boy with congenital hearing loss. Read more here.
0
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month
https://www.fool.com/investing/2024/02/08/heres-why-merck-eli-lilly-and-novo-nordisk-stocks/?source=iedfolrf0000001
Feb 08, 2024 - Investors are still excited about obesity treatments and weight-management drugs.
0